MX2020001820A - Metodos para reforzar las respuestas inmunitarias. - Google Patents

Metodos para reforzar las respuestas inmunitarias.

Info

Publication number
MX2020001820A
MX2020001820A MX2020001820A MX2020001820A MX2020001820A MX 2020001820 A MX2020001820 A MX 2020001820A MX 2020001820 A MX2020001820 A MX 2020001820A MX 2020001820 A MX2020001820 A MX 2020001820A MX 2020001820 A MX2020001820 A MX 2020001820A
Authority
MX
Mexico
Prior art keywords
methods
immune responses
boosting immune
relates
boosting
Prior art date
Application number
MX2020001820A
Other languages
English (en)
Spanish (es)
Inventor
Kumar Arora Ashwani
Weynants Vincent
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2020001820A publication Critical patent/MX2020001820A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020001820A 2017-08-14 2018-08-13 Metodos para reforzar las respuestas inmunitarias. MX2020001820A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545010P 2017-08-14 2017-08-14
US201862633263P 2018-02-21 2018-02-21
PCT/EP2018/071860 WO2019034575A1 (en) 2017-08-14 2018-08-13 Methods of boosting immune responses

Publications (1)

Publication Number Publication Date
MX2020001820A true MX2020001820A (es) 2020-03-20

Family

ID=63350516

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001820A MX2020001820A (es) 2017-08-14 2018-08-13 Metodos para reforzar las respuestas inmunitarias.

Country Status (8)

Country Link
US (1) US11723966B2 (enExample)
EP (1) EP3641808A1 (enExample)
JP (2) JP2020530478A (enExample)
CN (1) CN110996994A (enExample)
BR (1) BR112020001768A2 (enExample)
CA (1) CA3072018A1 (enExample)
MX (1) MX2020001820A (enExample)
WO (1) WO2019034575A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022543264A (ja) * 2019-08-05 2022-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロテインｄポリペプチドを含む組成物を調製するプロセス
EP4294433A1 (en) * 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Immunogenic composition, use and methods
WO2023194971A2 (en) * 2022-04-08 2023-10-12 St. Jude Children's Research Hospital Immunogenic compositions and methods for reducing transmission of pathogens

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) * 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69740108D1 (de) * 1996-12-20 2011-03-10 Univ Texas Moraxella catarrhalis antigene uspa1 und uspa2
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
EP2292632A3 (en) 2000-09-26 2012-07-25 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
WO2007018463A2 (en) * 2005-08-10 2007-02-15 Arne Forsgren Ab Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
MX2008009280A (es) 2006-01-17 2008-12-12 Arne Forsgren Una nueva proteina de haemophilus influenzae expuesta en la superficie (proteina e; pe).
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途

Also Published As

Publication number Publication date
CA3072018A1 (en) 2019-02-21
CN110996994A (zh) 2020-04-10
EP3641808A1 (en) 2020-04-29
US11723966B2 (en) 2023-08-15
WO2019034575A1 (en) 2019-02-21
JP2020530478A (ja) 2020-10-22
US20200197504A1 (en) 2020-06-25
BR112020001768A2 (pt) 2020-09-29
JP2023103380A (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
PH12019501533A1 (en) Tigit-and light-based chimeric proteins
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
MX376079B (es) Construcciones de proteina superficial ubicua a2 y usos de las mismas.
NZ761568A (en) Anti-cd47 antibodies and uses thereof
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
MX2020009326A (es) Anticuerpos anti-claudina 18.2 y usos de los mismos.
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
PH12018500578A1 (en) Methods of treating inflammatory diseases
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
EA201890355A1 (ru) Новые способы индукции иммунного ответа
JOP20190134A1 (ar) بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
WO2017027757A3 (en) Smallpox vaccine for use in cancer treatment
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
MX2018005462A (es) Composiciones inmunogénicas de rsv quimérico y métodos de uso.
WO2016179034A3 (en) Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
MX2022001488A (es) Composicion inmunogenica.
MX2022009171A (es) Composiciones para el tratamiento de dermatitis atopica canina y sus usos.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
SE1500434A1 (en) A novel fusion partner for highly efficient and safe vaccines
WO2016091890A8 (en) Meningitidis vaccines comprising subtilinases